Risk Factors for Failure of Early Catheter Removal After Greenlight HPS Laser Photoselective Vaporization Prostatectomy in Men With Benign Prostatic Hyperplasia
- PMID: 23362445
- PMCID: PMC3556551
- DOI: 10.4111/kju.2013.54.1.31
Risk Factors for Failure of Early Catheter Removal After Greenlight HPS Laser Photoselective Vaporization Prostatectomy in Men With Benign Prostatic Hyperplasia
Abstract
Purpose: To assess the risk factors for developing urinary retention after removal of the urethral catheter on postoperative day 1 in benign prostatic hyperplasia patients who underwent Greenlight HPS laser photoselective vaporization prostatectomy (PVP).
Materials and methods: The study included 427 men who underwent Greenlight HPS laser PVP between 2009 and 2012, excluding patients in whom a catheter was maintained for more than 1 day because of urethral procedures. In all patients, a voiding trial was performed on postoperative day 1; if patients were unable to urinate, the urethral catheter was replaced before hospital discharge. The patients were divided into two groups: early catheter removal (postoperative day 1) and late catheter removal (urethral catheter reinsertion). Preoperative and perioperative parameters were compared between the groups.
Results: Catheters were successfully removed in 378 (88.6%) patients on postoperative day 1. In 49 patients, the catheters were reinserted and removed a mean of 6.45±0.39 days after surgery. In a multivariate analysis, a history of diabetes was the most significant predictor (p=0.028) of failure of early catheter removal, followed by operative time (p=0.039). There were no significant differences in age, prostate volume, International Prostate Symptom Score, or urodynamic parameters between the two groups.
Conclusions: It is feasible, safe, and cost-effective to remove the urethral catheter on postoperative day 1 after Greenlight HPS laser PVP, but the procedure should be done carefully in patients who have history of diabetes or an extended operative time.
Keywords: Laser therapy; Prostatic hyperplasia; Urethral catheterization.
Conflict of interest statement
The authors have nothing to disclose.
Similar articles
-
Intermediate outcomes of GreenLight HPS™ laser photoselective vaporization prostatectomy for symptomatic benign prostatic hyperplasia.J Endourol. 2011 Jun;25(6):1037-41. doi: 10.1089/end.2010.0512. Epub 2011 May 16. J Endourol. 2011. PMID: 21574860 Clinical Trial.
-
Short-term outcomes of Greenlight HPS laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH).J Endourol. 2008 Oct;22(10):2341-7. doi: 10.1089/end.2008.9708. J Endourol. 2008. PMID: 18937595 Clinical Trial.
-
Urinary Retention After GreenLight Laser Photoselective Vaporization of the Prostate (GLL.PVP) Surgery for Benign Prostatic Hyperplasia (BPH): A 3-6 Month Retrospective Follow-Up Study.Cureus. 2024 Nov 13;16(11):e73585. doi: 10.7759/cureus.73585. eCollection 2024 Nov. Cureus. 2024. PMID: 39540197 Free PMC article.
-
GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up.Eur Urol. 2011 Oct;60(4):734-9. doi: 10.1016/j.eururo.2011.05.043. Epub 2011 Jun 1. Eur Urol. 2011. PMID: 21658839 Clinical Trial.
-
Holmium:YAG transurethral incision versus laser photoselective vaporization for benign prostatic hyperplasia in a small prostate.J Urol. 2014 Jan;191(1):148-54. doi: 10.1016/j.juro.2013.06.113. Epub 2013 Jul 8. J Urol. 2014. PMID: 23845460
Cited by
-
Effect of saline perfusion before catheter removal in patients with BPH treated with GreenLight laser photoselective vaporization of the prostate.Am J Clin Exp Urol. 2024 Jun 25;12(3):134-140. doi: 10.62347/ZWRQ6068. eCollection 2024. Am J Clin Exp Urol. 2024. PMID: 39021397 Free PMC article.
-
Enhanced recovery after surgery in transurethral surgery for benign prostatic hyperplasia.Asian J Androl. 2023 May-Jun;25(3):356-360. doi: 10.4103/aja202267. Asian J Androl. 2023. PMID: 36254889 Free PMC article.
-
A novel vaporization-enucleation technique for benign prostate hyperplasia using 120-W HPS GreenLight™ laser: Seoul technique II in comparison with vaporization and previously reported modified vaporization-resection technique.World J Urol. 2017 Dec;35(12):1923-1931. doi: 10.1007/s00345-017-2091-8. Epub 2017 Sep 23. World J Urol. 2017. PMID: 28942591
References
-
- Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol. 2000;163:13–20. - PubMed
-
- Stovsky MD, Griffiths RI, Duff SB. A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia. J Urol. 2006;176(4 Pt 1):1500–1506. - PubMed
-
- Al-Ansari A, Younes N, Sampige VP, Al-Rumaihi K, Ghafouri A, Gul T, et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol. 2010;58:349–355. - PubMed
-
- Agrawal SK, Kumar AS. Early removal of catheter following transurethral resection of the prostate. Br J Urol. 1993;72:928–929. - PubMed
-
- Drago JR. Transurethral incision of prostate. Urology. 1991;38:305–306. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources